CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels Associations between Blood Lead Levels and Coronary Artery Stenosis Measured Using Coronary Computed Tomography Angiography Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Association of All-Cause and Cardiovascular Mortality With High Levels of Physical Activity and Concurrent Coronary Artery Calcification Long-term effects of intensive glucose lowering on cardiovascular outcomes

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008